Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Sarkar, Subhashis ^a   Germeraad, Wilfred T V ^a   Rouschop, Kasper M A ^b   Steeghs, Elisabeth M P ^a   van Gelder, Michel ^a   Bos, Gerard M J ^a   Wieten, Lotte ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; INTERLEUKIN 2; LYMPHOCYTE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; PERFORIN; PROTEIN 2B4; PROTEIN DNAM1; PROTEIN KIR; PROTEIN MICA; PROTEIN MICB; PROTEIN NCR; PROTEIN ULBP1; PROTEIN ULBP2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL HYPOXIA; CELL ISOLATION; CELL THERAPY; CONTROLLED STUDY; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

CELL DEGRANULATION; CELL HYPOXIA; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OXYGEN; PERFORIN; RECEPTORS, IGG;

EID: 84878404499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064835     Document Type: Article

References (39)

1. Delorme S, Baur-Melnyk A, (2009) Imaging in Multiple Myeloma. Eur J Radiol 70: 401-408.
2. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, et al. (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258.
3. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, et al. (2008) Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 143: 641-653.
4. Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, et al. (2008) Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111: 3155-3162.
5. Katodritou E, Terpos E, North J, Kottaridis P, Verrou E, et al. (2011) Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells. Am J Hematol 86: 967-973.
6. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, et al. (2012) Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 97: 1348-1356.
7. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, et al. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286-2294.
8. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, et al. (2012) A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120: 4324-4333.
9. Harris AL, (2002) Hypoxia-A key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47.
10. Watanabe Y, Terashima Y, Takenaka N, Kobayashi M, Matsushita T, (2007) Prediction of avascular necrosis of the femoral head by measuring intramedullary oxygen tension after femoral neck fracture. J Orthop Trauma 21: 456-461.
11. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD, (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104: 5431-5436.
12. Rehn M, Olsson A, Reckzeh K, Diffner E, Carmeliet P, et al. (2011) Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche. Blood 118: 1534-1543.
13. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, et al. (2012) Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119: 5782-5794.
14. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, et al. (2010) Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116: 1524-1527.
15. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, et al. (2010) Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24: 1967-1970.
16. Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, et al. (2010) Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 30: 2831-2836.
17. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, et al. (2010) Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95: 776-784.
18. Rohwer N, Cramer T, (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.
19. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, et al. (2011) Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71: 7433-7441.
20. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, et al. (2008) Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68: 4746-4753.
21. Loeffler DA, Juneau PL, Heppner GH, (1991) Natural killer-cell activity under conditions reflective of tumor micro-environment. Int J Cancer 48: 895-899.
22. Fink T, Ebbesen P, Koppelhus U, Zachar V, (2003) Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scand J Immunol 58: 607-612.
23. Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, et al. (2008) A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 93: 1049-1057.
24. Alter G, Malenfant JM, Altfeld M, (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15-22.
25. Helmlinger G, Yuan F, Dellian M, Jain RK, (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182.
26. Guitart AV, Hammoud M, Dello Sbarba P, Ivanovic Z, Praloran V, (2010) Slow-cycling/quiescence balance of hematopoietic stem cells is related to physiological gradient of oxygen. Exp Hematol 38: 847-851.
27. Ljunggren HG, Malmberg KJ, (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7: 329-339.
28. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, et al. (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28: 955-959.
29. Sutlu T, Alici E, (2009) Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 266: 154-181.
30. Chávez-Blanco A, De la Cruz-Hernández E, Domínguez GI, Rodríguez-Cortez O, Alatorre B, et al. (2011) Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol 39: 1491-1499.
31. Nausch N, Cerwenka A, (2008) NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
32. Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, et al. (2012) Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 30: 266-279.
33. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC, (2011) The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 25: 1533-1542.
34. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA, (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17: 6287-6297.
35. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, et al. (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71: 6621-6632.
36. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, et al. (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 105: 1285-1290.
37. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, et al. (2009) The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 182: 3510-3521.
38. Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, et al. (2012) Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res 36: 122-124.
39. Frings PW, Van Elssen CH, Wieten L, Matos C, Hupperets PS, et al. (2011) Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. Breast Cancer Res Treat 130: 773-781.